RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor

Ann Oncol. 2019 Jul 1;30(7):1170-1172. doi: 10.1093/annonc/mdz125.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Azetidines / administration & dosage
  • Drug Resistance, Neoplasm / genetics*
  • Gene Deletion*
  • Humans
  • Imidazoles / adverse effects*
  • Langerhans Cell Sarcoma / drug therapy*
  • Langerhans Cell Sarcoma / pathology
  • MAP Kinase Kinase 1 / antagonists & inhibitors
  • Male
  • Middle Aged
  • Mutation*
  • Neoplasm Recurrence, Local / chemically induced
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / pathology
  • Oximes / adverse effects*
  • Piperidines / administration & dosage
  • Prognosis
  • Protein Kinase Inhibitors / adverse effects
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Vemurafenib / administration & dosage
  • p120 GTPase Activating Protein / genetics*

Substances

  • Azetidines
  • Imidazoles
  • Oximes
  • Piperidines
  • Protein Kinase Inhibitors
  • RASA1 protein, human
  • p120 GTPase Activating Protein
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human
  • cobimetinib
  • dabrafenib